Antibiotic Ensanchomycin

ABSTRACT

This invention relates to a new phosphorous-containing antibiotic designated MSD 820A, and is hereafter known as Ensanchomycin. The antibiotic is produced by culturing the microorganism Streptomyces cinnamonensis or the microorganism Streptomyces melanogenes. Ensanchomycin possesses antibacterial activity against both gram-positive and gram-negative bacteria. This invention relates to a new antibiotic substance, to methods for its use, production by fermentation and also to methods for its concentration, purification and isolation.

United States Patent 1191 Stapley et al.

[ Dec. 16, 1975 I ANTIBIOTIC ENSANCI-IOMYCIN [75] Inventors: Edward O. Stapley, Metuchen, N.J.; Justo Martinez Mata, Madrid, Spain [73] Assignee: Merck & Co., Inc., Rahway, NJ.

[22] Filed: June 7, 1974 [21] Appl. No.: 477,251

Related US. Application Data [62] Division of Ser. No. 415,185, Nov. 12, 1973.

[52] US. Cl. 424/118 [51] Int. Cl. H6lk 21/00 [58] Field of Search 424/118 [56] References Cited OTHER PUBLICATIONS Miller, The Pfizer Handbook of Microbial Metabolites, McGrawHill Book Co., Inc., N.Y., N.Y., I961, pp. 397.and 429.

Primary ExaminerJerome D. Goldberg Attorney, Agent, or FirmWalter Patton; Julian S. Levitt; Rudolph J. Anderson, Jr.

[57] ABSTRACT This invention relates to a new phosphorouscontaining antibiotic designated MSD 820A, and is hereafter known as Ensanchomycin. The antibiotic is produced by culturing the microorganism Streptomyces cinnamonensis or the microorganism Streptomyces melanogenes. Ensanchomycin possesses antibacterial activity against both gram-positive and gram-negative bacteria. This invention relates to a new antibiotic substance, to methods for its use, production by fermentation and also to methods for its concentration, purification and isolation.

4 Claims, 1 Drawing Figure 22 5 5 ss 3: as 2% gum U.S. Patent Dec. 16, 1975 ELF ANTIBIOTIC ENSANCHOMYCIN This is a division of application Ser. No. 415,185 filed Nov. 12, 1973.

The search for novel antibiotics is a continuing one because the activity of the known antibiotics is usually effective against only a limited number of pathogenic microorganisms. In addition to this limited spectrum of activity, it has been found that certain strains of some pathogens have been able to develop a resistance to particular antibiotics and, as a result, the antibiotics no longer are as effective against these resistant strains.

The main object of this invention is to provide a new and useful antibiotic which is effective in inhibiting the growth of pathogenic bacteria. Another object of this invention is to provide a process for preparing this antibiotic by the fermentation of a nutrient medium with suitable strains of the microorganisms described below.

This new antibiotic is another phosphorus-containing antibiotic related to the growing family of phosphorous-containing antibiotics which includes among others, the previously described compounds: diumycin, umbrinomycin, and moenomycin.

The new antibiotic possesses all of the antimicrobial properties of the known phosphorous-containing antibiotics including activity against gram-positive bacteria such as bacilli, staphylococci, streptococci and diplococci and gram-negative bacteria such as Escherichia coli, Proteus vulgaris and Salmonella schottmuelleri. The new antibiotic Ensanchomycin has a broad spectrum of activity against gram-negative bacteria and has been found to be active against Pseudomonas.

In addition to its antibiotic activity, Ensanchomycin is an effective growth promoter in animals when administered orally.

The new antibiotic substance of the present invention is formed by growing, under controlled conditions, a previously unknown strain of the microorganism Streptomyces cinnamonensis. In addition, the antibiotic may also be prepared by growing a previously unknown strain of the microorganism S treptomyces melanogenes.

, The Streptomyces cinnamonensis microorganism was isolated from a sample of soil from the Cata Mountains (Alicante) in Spain. This newly isolated strain of microorganism has been designated as MA-287l in the culture collection of Merck & Co., Inc., Rahway, NJ. A culture has been deposited without restrictions as to availability with the Fermentation Section of the Northern Utilization Research Branch, US. Department of Agriculture at Peoria, 111., and is added to its permanent culture collection, and is available to the public under culture No. NRRL 5751.

The other microorganism Strepzomyces melanogenes was isolated from a sample of soil from near Madrid, Spain. This strain of microorganism has been designated as MA-2873 in the culture collection of Merck & Co., Inc., Rahway, N]. A culture thereof has been deposited without restriction as to availability with the Fermentation Section of the Northern Utilization Research Branch, US. Department of Agriculture at Peoria, Ill., and added to its permanent culture collection, and is available to the public under Culture No. NRRL 5752.

The morphological and cultural characteristics of Streptomyces cinnamonensis are set forth in the following table.

Morphology Sporophores are hooks, loops and few loose spirals, occurring as side branches on aerial hyphae. Spores are in chains of more than 10 spores spherical to oval, 0.9a diameter and 0.9 X l.2,u..

Cultural 1 Tomato paste-oatmeal agar --Vegetative growth Dark brown; Aerial mycelium Moderate, velvety, Vegetative rose beige (4ec); Soluble pigment Brown.

Czapek Dox agar Vegetative growth -Brown to dark brown; Aerial mycelium Moderate, light rose-beige (4ec); Soluble pigment Light brown.

Glycerol-asparagine agar Vegetative growth Brown to dark brown; Aerial mycelium Moderate, flesh-pink with beige undertone (4ca); Soluble pigment Light pinkish brown.

Egg Albumin agar Vegetative growth Brown to dark brown; Aerial mycelium Scant, brownish; Soluble pigment Light brown.

Synthetic starch agar Vegetative growth Tan to brown; Aerial mycelium Moderate, flesh pink with beige undertone (4ca); Soluble pigment Light pinkish brown.

Yeast extract-dextrose-salts agar Vegetative growth Brown to dark brown; Aerial mycelium Moderate, light rose beige (4ec); Soluble pigment Brown.

Calcium malate agar Vegetative growth Cream colored; Aerial mycelium Moderate, very pale flesh pink; Soluble pigment None; Utilizes malate.

Nutrient agar Vegetative growth Tan; Aerial mycelium None; Soluble pigment Light brown.

Skim milk agar Vegetative growth Dark brown; Aerial mycelium Moderate, light rose-beige (4ec); Soluble pigment Brown; Hydrolyzes casein.

Litmus milk Vegetative growth Moderate growth ring; Brown; Aerial mycelium Scant, whitish; Complete peptonization, becoming alkaline (pH 7.9).

Skim milk Vegetative growth Moderate growth ring, dark brown; Aerial mycelium Scant, tannish; Soluble pigment Brown; Peptonization almost complete; Alkaline (pH 8.0).

Nutrient gelatin agar Vegetative growth Light brown; Aerial mycelium None; Soluble pigment Brown; Liquefaction good.

Gelatin Stabs Vegetative growth Tan; Aerial mycelium None; Soluble pigment Greenish brown; Liquefaction complete.

Nutrient starch agar Vegetative growth Tan; Ae-

rial mycelium Scant, whitish; Soluble pigment Light Brown; Starch hydrolysis good.

Nutrient tyrosine agar Vegetative growth Dark brown, almost black; Aerial mycelium Sparse, tannish; Soluble pigment Dark brown; Decomposes tyrosine crystals.

Pepton-iron-yeast extract agar Vegetative growth Dark brownish gray to black; Aerial mycelium None; Soluble pigment Dark brown to black; Melanin positive; H 8 production positive.

Temperature range (Yeast extract-dextrose-salts agar) 50C. No growth; 37C. Moderate growth; 28C. Good growth.

Potato plugs Vegatative growth Dark brownish gray; Aerial mycelium None; Soluble pigment Dark brown; Liquefaction good.

Loefflers Blood Serum Agar Vegetative growth Dark gray; Aerialmycelium None; Soluble pigment Dark brown; Liquefaction good.

Aerobic.

Nitrate reduction positive.

Carbohydrate utilization (Pridham-Gottlieb basal medium 1% carbohydrate) Glucose, arabinose, fructose, inositol, lactose, maltose, mannitol, rafflnose, rhamnose, sucrose and xylose are utilized for growth. Cellulose is not utilized.

All readings were taken after three weeks incubation at The pH of all media is approximately neutral 6.8-7.2).

Color designations are from Color Harmony Manual,

4th Edition, 1958, Container Corporation of America, Chicago, Ill.

i The morphological and cultural characteristics of Streptomyces melanogenes are set forth in the following table.

Morphology Sporophores branched, flexuous, some with hooks and loops. Spores are in chains of more than spores, cylindrical, 0.9;.1. l.2p..

Cultural Tomato paste-oatmeal agar Vegetative growth Reverse brown; Aerial mycelium Cream colored, velvety; Soluble pigment Tan.

Czapek Dox agar Vegetative growth Yellowish; Aerial mycelium Scant, whitish; Soluble pigment Tannish.

Glycerol-asparagine agar Vegetative growth Reverse reddish brown; Aerial mycelium Velvety, pale rose beige (4ec); Soluble pigment Dark reddish brown.

Egg albumin agar Vegetative growth Reverse dark brown; Aerial mycelium Velvety, pale rosebeige (4ec); Soluble pigment Dark brown.

Synthetic starch agar Vegetative growth Reverse colorless to tan; Aerial mycelium Cottony white; Soluble pigment None; Hydrolysis of starch Moderate.

Nutrient starch agar Vegetative growth Tan; Ae-

rial mycelium Moderate, brownish white; Soluble pigment Light brown along growth streak; Hydrolysis of starch Moderate.

Nutrient gelatin agar Vegetative growth Tan; Aerial mycelium Brownish white; soluble pigment Brown; Liquefaction of gelatin Good.

Gelatin stabs Vegetative growth Greenish tan growth ring; Aerial mycelium None; Soluble pigment Dark greenish brown; Liquefaction of gelatin Complete.

Skim milk agar plates Vegetative growth Brown to grayish-brown; Aerial mycelium None; Soluble pigment Dark brown; Some hydrolysis of casein.

Litmus milk Vegetative growth Heavy dark brown growth ring; Aerial mycelium Sparse, grayish; Soluble pigment Dark brown; Partial peptonization pH remaining about the same as pH of control tube.

Skim milk Vegetative growth Moderate, brown to tan growth ring; Aerial mycelium Sparse, brownish; Soluble pigment Dark brown; Partial peptonization pH about the same as that of control tube.

Nutrient tyrosine agar Vegetative growth Dark brown, almost black; Aerial mycelium Gray in center, grayish-cream along edges; Soluble pigment Brown; Decomposes tyrosine crystals.

Loeffler Blood Serum Slants Vegetative growth Dark gray; Aerial mycelium None; Soluble pigment Black beneath cultures shading to gray; Liquefaction Moderate.

Potato plugs Vegetative growth Dark brown;

Aerial mycelium Cottony, cream to grayishcream; Soluble pigment Moderate darkening of plug.

Nutrient agar Vegetative growth Tan, spreading; Aerial mycelium Scant, whitish; Soluble pigment Light brown.

Peptone-yeast extract iron agar Vegetative growth Dark gray to black; Aerial mycelium None; Soluble pigment Dark brown to almost black; Melanin Positive; H 8 production positive.

Temperature range (Yeast extract-dextrose-salts agar) 50C. No growth; 37C. Moderate growth; 28C. Good growth.

Aerobic.

Nitrate reduction positive.

Carbohydrate utilization (Pridham-Gottlieb basal medium 1% carbohydrate) Glucose, arabinose, fructose, inositol, lactose, maltose, mannose, mannitol, sucrose, xylose, raffinose and rhamnose are utilized for growth. Cellulose is not utilized.

Color designations from Color Harmony Manual, 4th Edition, 1958, Container Corporation of America, Chicago, Ill.

All readings were taken after three weeks incubation at 28C. except where noted. The pH of all media is approximately neutral (6.87.2).

The above description of the microorganisms producing Esanchomycin is given as illustrative of the strains of Streptomyces cinnamonensis (MA-2871) and Streptomyces melanogenes (MA-2873) which can be employed in the production of Ensanchomycin. However, the present invention also embraces mutant species of the above described microorganisms. For example, those mutants which are obtained by natural selection or those produced by mutating agents including X-ray irradiation, ultraviolet irradiation or nitrogen mustards or like treatments.

PHYSICAL CHARACTERISTICS Ensanchomycin reacts like an acidic organic compound and is soluble in alkaline solutions such as aqueous solutions of the alkali metal hydroxides, carbonates or bicarbonates which forms the corresponding salts. Also, Ensanchomycin reacts with other bases such as ammonia and the like.

Ensanchomycin as its ammonium salt has been degraded by strong acid hydrolysis (4N hydrochloric acid at C. for six hours) to yield the following degradation products: ammonia, and glucosamine. However, there was no 6-deoxyglucosamine.

A solution of Ensanchomycin in 0.lN hydrochloric acid exhibits an ultraviolet absorption with a peak at A max. 247 nm (E 63.3).

A solution of Ensanchomycin in 0.lN sodium hydroxide exhibits an ultraviolet absorption with a peak at )t max. 258 nm (E W 104).

The infrared absorption spectrum of Ensanchomycin ammonium salt in a mineral oil (Nujol) is reproduced in FIG. 1 in the drawing.

Ensanchomycin contains the elements carbon, hydrogen, nitrogen, phosphorous and oxygen. The following is an elemental analysis of Ensanchomycin ammonium salt:

lated from the survival records obtained on the seventh Carbon 47,11 percent day after infection by the Method of Knudson & Curtis Hydrogen Percent (J. Amer. Statist. Assoc. 42:282-296, 1947). Nitrogen 7.67 percent Phosphorous 1.93 percent TABLE 2 Oxygen 36.39 percent I (by difference) Route of EDso gldose lnfectin g Organism Therapy According to the micro-analytical data, Ensanchomy- Pmmmwia" 3 cm ammonium salt has the approximate empirical forsmphylommw gums 2949 ip Q] 51 mula: C l-l N O P with a calculated molecular Sc 28 p0 weight of 1600.6. Titration of aqueous solutlon of snepmocws Wage: 3009 ip 0.004 Ensanchomycm ammonium salt indicates an equivalent sc (2). 7 27 p0 weight of 1477, and a pK 4.6. The material employed Klebsiella pneumoniae 3068 ip to determine the above physical characteristics was Proteus mirabilis 3201 ip 10.0* obtained from Example 4 below Proteus morganii 3202 ip 6.7

Y Proteus rulgaris 1810 ip 5.33 Pseudomonas aeruginosa 2616 ip 3.37 IN Pseudnmonas aeruginosa 3210 ip 3.34 A sample of Ensanchomycin was assayed in a series Salmamu ip 33 of agar diffusion assays. A broad spectrum of activity was obtained and is summarized in Table l. in i hlraperitoneal sc subcutaneous Methods p0 oral *Significant prolongation of survival time (p 0.01 for Klebsiella and 0.005 for P.

Th sa e as ys are perfonned placlng paper dlscs of mirabilis, where p=significance level).

one-fourth inch diameter (7 mm.), previously immersed into a distilled water solution of Ensanchomy Girl, On the surface Of 100 mm. petri plates containing 5 Ensanchomycin is useful both as an antibiotic and as ml. of inoculated nutrient agar with 0.2 percent yeast 3 growth promolmg agent m ammalsextract. With the exception of Bacillus subtilis which is Ensanchomycm can be used as l annblotlcq for used as a spore suspension, the agar is seeded with an exa'mple l f pharmaceutlfial pf p overnight culture grown undelappropriate conditions which contain 'it in admixture or con unction With an (See Table 1 and diluted with nutrient broth to 1 organlc or lnorgamc, SOlld or liquid pharmaceutical 0.22 at 660 nm. The diluted overnight inoculum is P sultablerfol' l f i Parenteral local added to agar at 33 or 6.6 percent (v/v) depending on mlnistration. Suitable exciplents are substances that do the organism. Plates are incubated overnight at temper- "P react withth antibiotic, for p Wafer, gela' r i di d i T bl 1 tln, lactose, starches, stearyl alcohol, magnesium stea- TABLE 1 Zones of Inhibition, mm. Culture lnoculum Organism Source*** Development 500 'y/ml. 250 'y/ml. 125 -y/ml.

Pseudomanas aeruginosa MB 979 NBYE, 37C., a 10 7' 7 Staphylococcus aureus ATCC 65381 NBYE, 37C., a 32 31 29 Bacillus sub/ills ATCC 6633 b. 37C., a 32 28 27 Staphylococcus aureus MB 698 NBYE. 37C., a 22 20 18 Alcaligenesfaecalis ATCC 213" NBYE, 37C., a l6 l4 l2 Vibrio percolaus ATCC 8461 NBYE, 28C., 6, d 19 16' 13 Xulu/mmuna: vasicaloria MB 815 AM;;*, 37C., a, d 10 7 7 Proteus rulgaris ATCC 21100 AM 37C., a, d 30 30 3O Escherichia coli MB 1418 AM 37C., a. d l4 l2 l0 Klebslella pneumoniae MB 1264 AM 37C., a, d 10 8 7 Aerabacler aerogenes MB 835 AM 37C., a, d 9 V 7 7 Staphylococcus aureus MB 3003 NBYE, 37C., a 23 21 18 Proteus \ulgaris MB 2146 NBYE, 37C., a 24 21 i9 Streptococcus agalactiae MB 2875 Bl-l, 37C., c 30 t 29 27 Streptococcus faecalis MB 753 BH, 37C., c l8 l4 l l a 3.3 percent (v/v) of diluted inoculum was added to the agar for plates.

b inoculum consists of 1 ml. of a refrigerated spore suspension diluted to 10 ml. with saline.

c 6.6 percent (v/v) of diluted inoculum was added to the agar for plates.

d lnoculum is grown on the shaker at 220 rpm. The remainder of the cultures are incubated stationary. *NBYE. AM; and BH refer to media for development of inocula.

NBYE nutrient broth 0.2 percent yeast extract:

AM; antibiotic medium No. 3 (Difco);

HR brain heart infusion broth.

' Plates are incubated at 37C.; plates for the remainder of cultures are incubated at 25C.

"MB Culture collection of Merck & Co.. lnc.. Rahway. N. 1.

IN VIVO ACTIVITY rate, talcum, vegetable oils, benzyl alcohols, gums,

Method propyleneglycol, polyalkyleneglycols, white petroleum White Swiss mice were infected intraperitoneally and jelly, cholesterol or other known medicinal excipients. treated by the route indicated in Table 2 at the time of The pharmaceutical preparations may be, for example, infection and again six hours later. Five mice were used tablets, dragees, ointments, creams or capsules, or in at each of the 4-fold antibiotic concentrations tested. liquid form solutions, suspensions or emulsions. They The amount of. antibiotic that should protect permay be sterilized and/or contain assistants, such as cent of the infected treated animals (ED is calcupreserving, stabilizing, wetting or emulsifying agents;

solution promoters, salts for regulating the osmotic pressure or buffers. v I

Where it is desired to administer the antibiotic in dry, solid unit dosage form, capsules, boluses or tablets containing the desired amount of antibiotic are employed. These dosage forms are prepared by intimately and uniformly mixing the active ingredient with suitable finely divided diluents, fillers, disintegrating agents and/or binders such as starch, lactose, talc, magnesium stearate, vegetable gums and the like.

Such unit dosage formulations may be varied widely with respect to their total weight and content of Ensanchomycin depending upon factors such as the type of host animal to be treated, the severity and type of infection and the weight of the host. The antibiotic may be administered on a daily basis at from about 20 to 200 mg. per kilograms of body weight.

Included in this invention are the non-toxic, pharmaceutically acceptable salts of Ensanchomycin, for example, the alkali and alkaline earth metal salts such as those derived from sodium, potassium, ammonium and calcium or salts with organic bases, for example, triethylamine, N-ethylpiperidine, dibenzylethylenediamine.

In addition to its use as an antibiotic, Ensanchomycin is useful as a feed additive to promote the growth of animals such as chickens, sheep and cattle. The use of Ensanchomycin shortens the time required for bringing animals up to marketable weight.

When Ensanchomycin is used as a growth promoter in animals, it can be administered as a component of the feed of the animals or may be dissolved or suspended in the drinking water.

When Ensanchomycin is used as a component of the animal feed, it is first formulated as a feed supplement. In such feed supplements, Ensanchomycin is present in relatively large amounts intimately dispersed in an inert carrier or diluent. The feed supplement can be added directly to the feed or made into a premix by an intermediate dilution or blending step. By inert carrier is meant one that will not react with the antibiotic and one that may be administered safely to animals. Preferably, the carrier is one that is, or may be, an ingredient of the animal ration. Typical carriers or diluents suitable for such compositions include, for example, distillers dried grains, corn meal, citrus meal, fermentation residues, ground oyster shells, wheat shorts, molasses solubles, corn cob meal, edible bean mill feed, soya grits, crushed limestone and the like. The antibiotic is intimately dispersed throughout the carrier by methods such as grinding, stirring, milling or tumbling. Compositions containing from about to 50% by weight of the antibiotic are particularly suitable as feed supplements.

Examples of typical feed supplements containing Ensanchomycin dispersed in a solid carrier are:

lbs.

(A) Ensanchomycin 5 Wheat Standard Middling 95 (B) Ensanchomycin 50 Com distillers grains 50 8 tion of between 50 gm. to 200 gm. per ton of feed in order to achieve the desired growth promoting result.

In the above discussion of this invention, emphasis has been placed on solid compositions wherein the Ensanchomycin is mixed with an edible carrier in a feed supplement, in a so-called premix or in the final poultry feedstuff. This is the preferred method of administering Ensanchomycin. An alternate method is to dissolve or suspend the Ensanchomycin in the drinking water of the animals. The quantity that may be suspended in the water without undue settling is limited. Emulsifiers or surface active agents may be employed for this latter purpose. I

It will likewise be understood by those skilled in this art that special feed supplement formulations and finished animal feeds containing Ensanchomycin may also include vitamins, other antibiotics and growth-promoting agents and other nutritional substances.

Ensanchomycin is produced during the aerobic fermentation of suitable aqueous media, under conditions described hereinafter, by strains of Streptomyces cinnamonensis and Streptomyces melanogenes. Aqueous media such as those used for the production of other antibiotics are suitable for the production of Ensanchomycin.

Such media contain sources of carbon and nitrogen assimilable by the microorganisms and inorganic salts. In addition, the fermentation media contain traces of metals necessary for the growth of the microorganisms which are usually present in complex sources of carbon and nitrogen of the medium.

In general, carbohydrates such as sugars, for example, dextrose, sucrose, maltose, lactose, dextran and the like, and starches, are suitable sources of assimilable carbon in the nutrient media. The exact quantity of the carbon source which is utilized in the medium will depend, in part, upon the other ingredients of the medium but it is usually found that the amount of carbohydrate between about 1 and 6 percent by weight of the medium is satisfactory. These carbon sources can be used individually or several such carbon sources may be combined in the medium.

Various nitrogen sources such as yeast hydrolysates, yeast autolysates, soybean meal, casein hydrolysates, corn steep liquors, distillers solubles, meat extract and the like, are readily assimilable by the new strains of Medium No. l (Agar Slant Culture) Yeast extract l0.0 g. Glucose l0.0 g. Phosphate buffer 2.0 ml. MgSO .7H O 0.05 g. Agar 20.0 g. Distilled H O l000.0 ml.

"Phosphate Buffer KH PO, 91.0 g. Na HPO, 95.0 g. Distilled H O 1000.0 ml.

-continued Medium No. 2 (For lnoculum Development) Beef extract 3.0 g. Casein hydrolysate Amber yeast BYF 300 Amber Laboratories The fermentation employing the Ensanchomycin producing microorganisms can be conducted at temperatures ranging from about to about 37C. For optimum results, we find it most convenient to conduct these fermentations. at a temperature in the range of from about 24 to about 32C. The pH of the nutrient medium suitable for producing Ensanchomycin can vary from about 5.0 to 9.0 with a preferred range of 6.0 to 7.5.

Small scale fermentations are conveniently carried out by placing suitable quantities of nutrient medium in a flask employing known sterile techniques, inoculating the flask with either spores or vegetative cellular growth of an Ensanchomycin producing strain of Streptomyces cinnamonensis or Streptomyces melanogenes, loosely stoppering the necks of the flasks with cotton and permitting the fermentation to proceed in a constant temperature room at about 28C. on a shaker for about 3 to 10 days. For larger scale work, it is preferable to conduct the fermentation in suitable tanks provided with an agitator and a means of aerating the fermentation medium. The nutrient medium is made up EXAMPLE 1 A culture of Streptomyces cinnamonensis strain MA- 2871 is produced by growing the organism on a sterile nutrient agar slant of the following composition:

Medium No. l (Agar Slant Culture) Yeast extract 10.0 g. Glucose 10.0 g. Phosphate buffer 2.0 ml. MgSO,.7l-1 O 0.05 g. Agar 20.0 g. Distilled H O 1000.0 ml.

-continued Medium No. l (Agar Slant Culture) Phosphate Buffer Distilled H O The slant is inoculated with spores and is incubated for one week at 28C. The culture obtained is used to inoculate a 250 ml. baffled Erlenmeyer flask containing 50 ml. of a sterile growth medium having the following composition:

Medium No. 2 (For lnoculum Development) Beef extract 3.0 g. Casein hydrolysate (NZ amine) Type E (Sheffield Chem. Corp) 10.0 g. Dextrose 10.0 g. Sodium Chloride 5.0 g. Distilled H O 1000.0 ml.

The seed flask is incubated on a 220 rpm. shaker (two inch throw) for 3 days at 28C. The contents of this seed flask is used to inoculate second stage seed flasks of the same composition as above. These were also incubated on a 220 rpm. shaker (two inch throw) for'3 days at 28C.

At the end of the 3 days incubation, the contents of the second stage flasks were pooled asceptically and used to inoculate (at 2.5 percent) 2-liter baffled Erlenmeyer flasks containing 350 ml. of sterile medium of the following composition:

Medium No. 3 Fermentation) Distillers solubles 20.0 g. Dextrose 10.0 g. Distilled H O 1000.0 ml.

EXAMPLE 2 A culture of Streptomyces melanogenes strain MA- 2873 is produced by growing the organism on a sterile agar slant of the following composition:

Medium No. l (Agar Slant Culture) Yeast extract 10.0 g. Glucose 10.0 g. Phosphate buffer 2.0 ml. MgSO JH O 0.05 g. Agar 20.0 g. Distilled H O 1000.0 ml.

Phosphate Buffer KH- .PO 91.0 g. NZI-ZHPO, 95.0 g.

-continued -continued Medium No. l (Agar Slant Culture) Medium A Distilled l-i. .o 1000.0 ml. Nan-1P0 95.0 g. 5 Distilled Water 1000.0 m1.

The slant is inoculated with spores and incubated for one week at 28C. They are then stored at 4C. until dTh lt bt' d' dt' It 250 Stagez am 0 g i 9 gg 10 Ten ml. of Medium B is added to slant culture from di fi l as 2?. a mmg m 0 me- Stage 1 and the growth is scraped into suspension and um e O Owmg composl used to inoculate 50 ml. of Medium B contained in a 250 ml. baffled Erlenmeyer flask. The flask culture is Medum 1 incubated on a rotary shaker at 28C. for 48 hours. Yeast extract 10.0 g. Freshly developed Stage 2 culture is used immediately slum to roceed to the next sta e Phosphate buffer 2.0 ml. p g

M so,.7ii o 0.05 g. Distilled H O 1000.0 m1 Phosphate Buffer Medium B KHzPOi 9L0 Dextrose 1.0% Na i-1P0 95.0 g- NaCl 0.5% Distilled 0000 NZ Amine Type E (Sheffield Chem. Corp.) 1.0% Meat Extract 0.3% Distilled H2O to Volume H 7.0 t 7.2 which is incubated on a 220 rpm. shaker (two 1nch p o throw) at 28C. for 3 days.

The contents of this seed flask is used .to inoculate (at 25 t 21' baffld-El H k h stag g p g f g i fi eac Ten ml. of vegetative growth from the Stage 2 flask is a m 0 me mm o e 0 owmg compo' used to inoculate 500 ml. of Medium B contained in a 30 2-liter baffled Erlenmeyer flask. The flask is incubated for 48 hours at 28C. on a rotary shaker and then used Medum 4 immediately to proceed to Stage 4. *Autolysed yeast 10.0 I g. Stage 4 82:1 :3 SOlubl 8 2' The contents of a Stage 3 flask (500 ml.) are used to Distilled H O 1000.0 ml. inoculate 467 liters of Medium B contained in 21200 PH m gallon stainless steel fermentor. Incubation in the fer- Amber yeast BYF 300 Amber Laboratories mentor is allowed to proceed for 65 hours at a temperature of 28C. with agitation at 130 rpm. and an air flow These flasks are incubated on a 35440 rpm Shaker of 10 cu. ft. per minute During incubation, defoamer (two inch throw) for 5 days. The contents of the flasks (Polyglycol 9 2000) used as q to control are pooled and a Sample centrifuged An assay, as foam, but not in excess of 0.1 percent. During the proscribed in Example 1, of this material gives an inhibi cedure of this fermentation, physiology determinations tion zone of 15 mm. against Proteus vulgaris (ATCC were made as follows: 21100) and 15 mm. against Vibrio percolans (ATCC 8461 Age in Hours pH Sugar (Dextrose) (mg/ml.)

0 6.4 9.5 12 6.4 9.5 EXAMPLE 3 24 6.3 9.0 36 5.5 4.7 Fermentation Process for Large Scale Preparation of 2(8) 7.4 0.3 7.9 0.3 Ensanchomycm 65 8'4 03 Stage l The contents of one lyophilized tube of Streptomyces cinnamonensis (MA-2871) are put into suspension in 2 Stage 5 ml. of Medium A. This suspension is used to inoculate The contents of the fermentor from Stage 4 (467 agar slants of Medium A solidified with 2 percent agar. liters) are used to inoculate 4,082 liters of Medium C Slant cultures were incubated at 289C. for 5 days or contained in a 1500 gallon stainless steel fermentor. until well sporulated. These cultures are used within Fermentation was allowed to proceed for 144 hours at tw ks f p p and stored at 5C ntil se. a temperature of 28C. with agitation at 120 rpm. and

air flow of 55.3 cu. ft. per minute. During the fermentation, defoamer (Polyglycol No. 2000) was added as required to control foam but not in excess of 0.1 per- Medium A cent Yeast Extract 10.0 g.

Dextrose (1)0.0 g.

*Phospllate Burrer 2.0 m1. Medum C Distilled Water 1000.0 ml.

pH 6.6 before sterilization 3:32: Solubles Water to Volume Determinations were made periodically of pH, dextrose concentration and antibiotic activity as follows:

14 liters per minute. The adsorbate was washed with 230 liters of water and then eluted with a step-wise gradient Assay performed by agar disc diffusion procedure (results in mm. of diameter of inhibition zone). using inch discs. "Assay procedure as described at page 10.

The Ensanchomycin was isolated and purified as described in Example 4.

EXAMPLE 4 Isolation and Purification of Ensanchomycin The filtrate from the 4082-liter batch of Example 3 above and the filtrates from two'400-liter fermentation batches prepared simultaneously with the above mentioned 4082-liter batch were combined to afford 5000 liters of filtrate. The filtrate had a total dissolved solids content of 28 mg. per ml. This was determined by evaporating, at 105C., a 1 ml. volume of the filtrate in a preweighed aluminum boat and weighing the residue. The pH of the filtrate was 8. If the pH was not 8, it was adjusted with either dilute hydrochloric acid or dilute sodium hydroxide solution to pH 8 in order to obtain best results with chromatography on Dowex resin.

The filtrate at a pH of 8 is adsorbed on Dowex l X 2 Cl (100 liters) resin at 10 liters per minute. The effluent stream is sampled every 500 liters and assayed against Proteus vulgaris (ATCC 21100). There is no 50 measurable breakthrough of antibiotic activity during the adsorption. The adsorbate is washed with water and then eluted with 500 liters of 70 percent methanol; 3 percent ammonium bicarbonate. Twenty-five fractions were collected of approximately 19 liters each. Each fraction was assayed against Proteus vulgaris (ATCC 21100). Fractions 6 to which contain 60 percent of the filtered broth activity, are combined and concentrated in vacuum at C. to 110 liters. The concentrate contained 3.06 kg. of total solids with approximately a 30-fold increase in potency. (A 120 mg. per ml. solution showed a 25 mm. zone of inhibition against Proteus vulgaris before chromatography and a 4 mg. per ml. solution showed the same inhibition after chromatography).

The eluate concentrate from above is adjusted to a pH of 7.0 with dilute hydrochloric acid and adsorbed on Amberlite XAD-Z (140 liters) at approximately 3 as follows: (1) 230 liters of 25 percent methanol; (2)

230 liters of 50 percent methanol; (3) 230 liters of percent methanol; and (4) 300 liters of percent methanol. The 25 percent methanol eluate is collected as one fraction; all other eluate streams are collected in 19-liter fractions. The overall recovery of charged bioactivity is 91 percent. The recovery breakdown is as follows: I) spent stream O; (2) waterwash 0; (3) 25 percent methanol 4.6 percent; (4) 50 percent methanol 29.0 percent; (5) 75 percent methanol 39.8 percent; and (6) 100 percent methanol 17.4 percent. The fractions containing the highest potency material is the 75 percent methanol fractions having an average of l6-fold increase in potency over the Dowex l X 2 eluate concentrate. Selected eluate fractions are com bined and concentrated to 1.5 liters at a pH of 7.0. The concentrate is filtered and freeze-dried to yield 79.5 g. with an average potency of 250 pg. per m1., equal to a Brinkman silica-gel (40 g.) is slurried in 100 to 20 n-propanol/ammonia (2N) and placed in a column. Five hundred mg. of the product obtained above is dissolved in 100 to 20 n-propanol/ammonia (2N) (5 ml.), and water (2 ml.) and applied to the column. The v column is developed with 200 ml. of a 100 to 20 propanol/2N ammonia; 200 ml. of an 80 to 20 solution; and 300 ml. of an 80 to 30 solution at a rate of 1 ml. per minute. A forerun (375 ml.) is collected and then 1.5 ml. fractions. A single bioactivity peak is observed between fractions 50 and when assayed against Proteus vulgaris (ATCC 21 100). Fractions 55 to 93 are combined and concentrated to 3 ml. and freeze-dried. The residue obtained is 115.7 mg. of the ammonium salt with a potency of pg. per ml. equal to a 25 mm. zone against Proteus vulgaris (ATCC 21100). This represents a 46 percent recovery with a two-fold purification. This sample is analyzed to afford the results.

reported above under the heading Physical Characteristics.

The following is a diagram of the method described in Example 4:

25 mm. zone against Proteus vulgaris (ATCC 21100).

FLOW SHEET ANTlBlOTlC PROCESS Fermentation Broth filtration Cake discarded Filtrate adsorbed on Dowex l X 2 Spent broth discarded Adsorbate eluted with 70% methanol containing 3% ammonium bicarbonate Fluate concentrated to aqueous solution Adsorbed on Amberlite XAD-Z Spent concentrate discarded Concentrated to aqueous solution Freeze-dried Ensanchomycin Silica-gel chromatography Fractions concentrated and freeze-dried EXAMPLE 5 Fermentation Process for the Production of Ensanchomycin Stage l 1 1 The contents of one lyophilized tube of Streptomyces melanogenes culture (MA-2873) were transferred, using aseptic techniques, into 2 to 3 ml. of Medium A. This suspension was used to inoculate agar slants of Medium A solidified with 2 percent agar. Slant cultures were incubated at 28C. for 5 days or'until well sporulated. These cultures were then stored at 5C. and used within two weeks of preparation.

Stage 3 The contents of the Stage 2 seed flask (500 ml.) were used to inoculate [60 liters of Medium D in a 50 gallon stainless steel fermentor. Incubation in the fermentor was allowed to proceed for 48 hours at a temperature of 28C., with agitation at 150 rpm. and airflow of 3 cu. ft. per minute. During incubation, defoamer (Polyglycol No. 2000) was used as required to control foam. During the fermentation, physiology determinations were made as follows:

Age (Hours) 0 12 24 36 48 40 pH 6.95 6.9 6.] 6.3 .725

sugar (dextrose) mg./ml. 9.2 8.9 5.6 0.8 0.3

Medium A Yeast Extract 10.0 g. Dextrose 10.0 g. MgSO .7H- O 0.05 g. Phosphate Buffer Z-O Stage 4 V A portion of the contents of the Stage 3 fermentor pH 6.6 before sterilization r (43 liters or 8.3% of the Stage 4 fermentor volume) was tg gg 91 0 g used to inoculate 467 liters of Medium D in a 200 3 6 5 g: gallon stainless steel fermentor. Fermentation was al- Disti led Water 1000-0 lowed to proceed for 96 to 120 hours at a temperature PH of 28C. with agitation at 130 rpm. and an airflow of 10 Medium B Dextrose l .0?! NaCl 0.5% NZ Amine Type E (Sheffield Chem. Corp.) L0 Meat Extract 0.3%

Distilled H O to Volume pH 7.0 to 7.2

cu. ft. per minute. During fermentation, defoamer (Polyglycol No. 2000) was used as required to control foam.

Medium D Distillers Solubles 2% Dextrose l7z Amber Yeast BYF 300 1% Water to Volume pH to 7.0 before sterilization Determinations were made periodically of pH, dextrose concentration and antibiotic activityas follows:

Age in Hours 12 24 36 4s 60 72 84 96 108 120 pH 6.5 5.9 6.0 6.9 7.3 7.7 8.1 8.1 8.2 8.3 8.3 Sugar (dextrose) mgJml. 9.5 6.0 0.7 0.6 0.4 0.3 0.2 Assay: S. aureus 21.5 24.5 24 24 24 22 22 18.5

P. vulgaris Halo 18 18.5 18 18.5 (MB-838) What is claimed is: 3. An antibacterial composition comprising an an- I. A method of promoting the growth of animals tibacterially effective amount of the antibiotic Ensanwhich comprises the administration to said animals of a chomycin, said antibiotic being characterized by the growth promoting amount of the antibiotic Ensanchofollowing properties: an ultraviolet absorption peak at mycin, said antibiotic being characterized by the fol- 247 my. in an acid solution and an ultraviolet absorplowing properties: an ultraviolet absorption peak at 247 tion peak at 258 my. in a basic solution having an inframp. in an acid solution and an ultraviolet absorption red spectrum in a Nujol mull as shown in FIG. 1, and an peak at 258 my. in a basic solution having an infrared elemental analysis of its ammonium salt as follows: C spectrum in a Nujol mull as shown in FIG. 1, and an 47.11 percent; H 6.90 percent; N 7.67 percent; elemental analysis of its ammonium salt as follows: C 20 phosphorus 1.93 percent; and O 36.39 percent (by 47.11 percent; H 6.90 percent; N 7.67 percent; difference) with the said ammonium salt having an phosphorus 1.93 percent; and O 36.39 percent (by approximate empirical formula of: C H N O P and a difference) with the said ammonium salt having an measured equivalent weight of 1477, and a pl(,, of 4.6, approximate empirical formula of: C H N O P and a or its pharmaceutically acceptable salts and a nontoxic measured equivalent weight of 1477, and 21 pl(,, of 4.6, 25 pharmaceutically acceptable carrier. or its pharmaceutically acceptable salts. 4. A composition for use in the growth promotion of 2. A method of treating bacterial infections in anianimals comprising a growth promoting amount of the mals which comprises the administration to said animal antibiotic Ensanchomycin, said antibiotic being charof an antibacterially effective amount of the antibiotic acterized by the following properties: an ultraviolet Ensanchomycin, said antibiotic being characterized by absorption peak at 247 mu in an acid solution and an the following properties: an ultraviolet absorption peak ultraviolet absorption peak at 258 my. in a basic soluat 247 my. in an acid solution and an ultraviolet absorption having an infrared spectrum in a Nujol mull as tion peak at 258 my. in a basic solution having an infrashown in FIG. 1 and an elemental analysis of its ammored spectrum in a Nujol mull as shown in FIG. 1, and an nium salt as follows: C 47.1 1 percent; H 6.90 perelemental analysis of its ammonium saltasfollows: C= cent; N 7.67 percent; phosphorus 1.93 percent; 47.11 percent; H 6.90 percent; N 7.67 percent; and O 36.39 percent (by difference) with the said phosphorus 1.93 percent; and O 36.39 percent (by ammonium salt having an approximate empirical fordifference) with the said ammonium salt having an mula of: C H N O P and a measured equivalent approximate empirical formula of: C H N O P and a weight of 1477, and a pK of 4.6, or its pharmaceutimeasured equivalent weight of 1477, and a pK of 4.6, 40 cally acceptable salts and a food supplement. or its pharmaceutically acceptable salts. 

1. A method of promoting the growth of animals which comprises the administration to said animals of a growth promoting amount of the antibiotic Ensanchomycin, said antibiotic being characterized by the following properties: an ultraviolet absorption peak at 247 m Mu in an acid solution and an ultraviolet absorption peak at 258 m Mu in a basic solution having an infrared spectrum in a Nujol mull as shown in FIG. 1, and an elemental analysis of its ammonium salt as follows: C 47.11 percent; H 6.90 percent; N 7.67 percent; phosphorus 1.93 percent; and O 36.39 percent (by difference) with the said ammonium salt having an approximate empirical formula of: C63H110N9O36P and a measured equivalent weight of 1477, and a pKa of 4.6, or its pharmaceutically acceptable salts.
 2. A METHOD OF TREATING BACTERIAL INFECTIONS IN ANIMALS WHICH COMPRISES THE ADMINISTRATION TO SAID ANIMAL OF AN ANTIBACTERIALLY EFFECTIVE AMOUNT OF THE ANTIOTIC ENSANCHOMYCIN, SAID ANTIBIOTIC BEING CHARACTERIZED BY THE FOLLOWING PROPERTIES: AN ULTRAVIOLET ABSORPTION PEAK AT 247 MU IN AN ACID SOLUTION AND AN ULTRAVIOLET ABSORPTION PEAK AT 258 MU IN A BASIC SOLUTION HAVING AN INFRARED SPECTRUM IN A NUJOL MULL AS SHOWN IN FIG. 1, AND AN ELEMENTAL ANALYSIS OF ITS AMMONIUM SALT AS FOLLOWS: C=47.11 PERCENT; H=6.90 PERCENT; N=7.67 PERCENT; PHOSPHORUS = 1.93 PERCENT; AND O = 36.39 PERCENT (BY DIFFERENCE) WITH THE SAID AMMONIUM SALT HAVING AN APPROXIMATE EMPIRICAL FORMULA OF: C63H110N9O36P AND A MEASURED EQUIVALENT WEIGHT OF 1477, AND A PKA OF 4.6, OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS.
 3. An antibacterial composition comprising an antibacterially effective amount of the antibiotic Ensanchomycin, said antibiotic being characterized by the following properties: an ultraviolet absorption peak at 247 m Mu in an acid solution and an ultraviolet absorption peak at 258 m Mu in a basic solution having an infrared spectrum in a Nujol mull as shown in FIG. 1, and an elemental analysis of its ammonium salt as follows: C 47.11 percent; H 6.90 percent; N 7.67 percent; phosphorus 1.93 percent; and O 36.39 percent (by difference) with the said ammonium salt having an approximate empirical formula of: C63H110N9O36P and a measured equivalent weight of 1477, and a pKa of 4.6, or its pharmaceutically acceptable salts and a nontoxic pharmaceutically acceptable carrier.
 4. A composition for use in the growth promotion of animals comprising a growth promoting amount of the antibiotic Ensanchomycin, said antibiotic being characterized by the following properties: an ultraviolet absorption peak at 247 m Mu in an acid solution and an ultraviolet absorption peak at 258 m Mu in a basic solution having an infrared spectrum in a Nujol mull as shown in FIG. 1, and an elemental analysis of its ammonium salt as follows: C 47.11 percent; H 6.90 percent; N 7.67 percent; phosphorus 1.93 percent; and O 36.39 percent (by difference) with the said ammonium salt having an approximate empirical formula of: C63H110N9O36P and a measured equivalent weight of 1477, and a pKa of 4.6, or its pharmaceutically acceptable salts and a food supplement. 